Linker Information
General Information of This Linker
| Linker ID |
LIN0NFAFY
|
|||||
|---|---|---|---|---|---|---|
| Linker Name |
Gly-Mal-Gly-Gly-Phe-Gly
|
|||||
| Antibody-Linker Relation |
Cleavable
|
|||||
| Structure |
|
|||||
| Formula |
C24H28N6O10
|
|||||
| Isosmiles |
O=C(O)CNC[C@@H](C(=O)NCC(=O)NCC(=O)N[C@@H](Cc1ccccc1)C(=O)NCC(=O)O)N1C(=O)C=CC1=O
|
|||||
| InChI |
InChI=1S/C24H28N6O10/c31-17(10-27-24(40)16(9-25-12-21(35)36)30-19(33)6-7-20(30)34)26-11-18(32)29-15(23(39)28-13-22(37)38)8-14-4-2-1-3-5-14/h1-7,15-16,25H,8-13H2,(H,26,31)(H,27,40)(H,28,39)(H,29,32)(H,35,36)(H,37,38)/t15-,16-/m0/s1
|
|||||
| InChIKey |
LYEUNXNIQUMXBE-HOTGVXAUSA-N
|
|||||
| Pharmaceutical Properties |
Molecule Weight
|
560.52
|
Polar area
|
240.41
|
||
|
Complexity
|
560.1866911
|
xlogp Value
|
-3.8851
|
|||
|
Heavy Count
|
40
|
Rot Bonds
|
16
|
|||
|
Hbond acc
|
9
|
Hbond Donor
|
7
|
|||
Each Antibody-drug Conjugate Related to This Linker
Full Information of The Activity Data of The ADC(s) Related to This Linker
BL-B01D1 [Phase 3]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Objective Response Rate (ORR) |
61.80% (NSCLC EGFR mutation)
40.50% (NSCLC EGFR wildtype) 14.30% (SCLC) 45.80% (NPC) 7.70% (HNSCC) |
|||
| Patients Enrolled |
Patients with locally advanced or metastatic solid tumors.
|
||||
| Administration Dosage |
BL-B01D1 was administered intravenously at doses of 2.50, 3.00 mg/kg D1D8 Q3W and 4.50, 5.00, 6.00 mg/kg D1 Q3W.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT05194982 | Clinical Status | Phase 1 | ||
| Clinical Description |
A phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of BL-B01D1 in patients with locally advanced or metastatic solid tumor.
|
||||
| Experiment 2 Reporting the Activity Date of This ADC | [2] | ||||
| Related Clinical Trial | |||||
| NCT Number | NCT05785039 | Clinical Status | Phase 2 | ||
| Clinical Description |
Phase 2a/2b clinical study to evaluate the safety, tolerability, pharmacokinetics and efficacy of BL-B01D1 for injection in patients with multiple solid tumors such as locally advanced or metastatic urinary system tumors.
|
||||
| Experiment 3 Reporting the Activity Date of This ADC | [3] | ||||
| Related Clinical Trial | |||||
| NCT Number | NCT05470348 | Clinical Status | Phase 1 | ||
| Clinical Description |
A phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of BL-B01D1 in patients with unresectable locally advanced or metastatic breast cancer and other solid tumors.
|
||||
| Experiment 4 Reporting the Activity Date of This ADC | [4] | ||||
| Related Clinical Trial | |||||
| NCT Number | NCT05393427 | Clinical Status | Phase 1 | ||
| Clinical Description |
A phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of BL-B01D1 in patients with locally advanced or metastatic urological tumors and other solid tumors.
|
||||
| Experiment 5 Reporting the Activity Date of This ADC | [5] | ||||
| Related Clinical Trial | |||||
| NCT Number | NCT05262491 | Clinical Status | Phase 1 | ||
| Clinical Description |
A phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of BL-B01D1 in patients with locally advanced or metastatic gastrointestinal tumor and other solid tumor.
|
||||
References